EDITOR’S NOTE: The project records
appearing every week in the Site Selection Project Bulletin are
pulled from the Conway Projects Database, a proprietary resource with tens of
thousands of records of corporate end-user facility investments across all industry
sectors and all world geographies. Want to look for our projects yourself? Look
here.
Kulim, Malaysia
Infineon Technologies’ investment
reaches new heights compared to its original investment announcement in February
2022.
Rendering courtesy of Infineon
If you thought semiconductor investments would slow anytime soon globally, you would be
wrong. While targeted investments seem to gear toward 300-millimeter chip productions,
Infineon Technologies AG is making moves to expand its Malaysia site into the world’s
largest 200-millimeter SiC Power Fab. The company announced this month its plans to invest
$5.4 billion over the next five years for the buildout of the expansion in Malaysia’s
state of Kedah. This massive investment comes on the heels of customer commitments from
six global OEMs and companies such as Ford, SAIC and Chery in the automotive sector and
several renewable energy customers. “The market for silicon carbide shows accelerating
growth, not only in automotive but also in a broad range of industrial applications such
as solar, energy storage and high-power EV charging. With the Kulim expansion, we will
secure our leadership position in this market,” said Infineon Technologies CEO Jochen
Hanebeck. “With the industry’s leading scale and a unique cost position, we are leveraging
our competitive position of best-in-class SiC trench technology, the broadest package
portfolio and unrivaled application understanding. These factors are the areas of
differentiation and success in the industry.” This project aims to keep in line with
sustainability goals in the country, as decarbonization goals look to reach net zero by
2050.
ADVERTISEMENT
Minamisōma City,
Japan
ARCALIS JV Partner Arcturus Therapeutics is based in
San Diego, California.
Photo courtesy of Arcturus Technologies
ARCALIS, a joint venture between California-based biotechnology company Arcturus and
Japan-based pharmaceutical company Axcelead, will soon develop mRNA vaccines and
therapeutics in Japan’s Minamisōma City, located an hour southeast of Fukushima. In doing
so, the JV recently received two grants from the Japanese government, totaling $115
million, for the construction of the facility and production equipment. The facility will
cover production of mRNA drug substance to bulk nanoparticle-formulated drug product in
line with current Good Manufacturing Practices. In addition to this project news Arcturus
announced that its LUNAR-FLU program has reached a $17.5 million milestone toward program
development from pharmaceutical corporation CSL Seqirus. Its STARR® mRNA vaccines, as part
of program development, will be manufactured at the site. “We are pleased with the
progress of the LUNAR-FLU program with CSL Seqirus, our exclusive global licensee for the
development of novel mRNA vaccines, and the significant role that Arcturus is playing in
the development activities,” said Arcturus Therapeutics President and CEO Joseph Payne.
“The LUNAR-FLU program could represent a major advance in vaccination efforts against flu,
potentially providing higher levels of efficacy and greater durability compared to current
flu vaccine approaches. We look forward to advancing this promising program.”
ADVERTISEMENT
Chungju, South
Korea
Chungju, South Korea, is adjacent to the country’s
largest lake, Chungjuho Lake, formed after the construction of Chungju
Dam.
Photo: Getty Images
As of today, China continues to lead the globe in the development of rare earth metals. Of
the 300,000 metric tons (MT) produced around the world, China contributes 210,000 MT of
domestic output. Supply chain resiliency remains top of mind for the country, leading to
pinpointed investments to distribute these materials for battery production. In August
2023, it was announced that not one, but two battery materials plants will soon call the
North Chungcheong province’s city of Chungju, South Korea, home within the next few years.
Of the combined $362 million investment made by China-based Ningbo Ronbay New Energy
Technology, approximately $273.2 million will be used to construct a nickel ternary
cathodes plant. This plant will work to produce 40,000 tons of annual output. Meanwhile,
the remaining $87.9 million will focus on a lithium ferromanganese phosphate cathodes
facility with an annual output of 20,000 tons. When it came to site selection for this
project, South Korea was strategic for helping the company connect to markets in Europe,
Japan and the United States, in addition to the country’s lack of export tariffs to U.S.
and European markets.
